G-CSF Diminishes the Toxicity of Remission Induction Therapy in Acute Lymphoblas
G-CSF Diminishes the Toxicity of Remission Induction Therapy in Acute Lymphoblastic Leukemia in Adults
ABSTRACT & COMMENTARY
Synopsis: A randomized study of 51 patients has shown that Granulocyte-Colony-Stimulation Factor significantly reduced the duration of neutropenia, the incidence of febrile neutropenia, and documented infections, and had no effect on the complete response rate or remission duration.
Source: Geissler K, et al. Blood 1997;90:590-596.
With the most recent advances in treatment, about 75% of adults with acute lymphoblastic leukemia (ALL) achieve a complete response. About 10% of patients die as a consequence of complications of the treatment induction, especially bacterial and fungal infections mainly related to marrow suppression. Granulocyte-Colony-Stimulating Factor (G-CSF) use during remission induction has not been extensively studied. Geissler and colleagues conducted a multicenter, randomized study in Austria of 51 patients with acute lymphoblastic leukemia. Patients were treated with a modification of the German Cooperative Multicenter ALL (GMALL) protocol in which a higher dose of daunorubicin (45 mg/m2) was used and a different, more potent preparation of asparaginase permitted reduction of the dose to 2500 U/m2.
G-CSF (5 mcg/kg) was given subcutaneously daily beginning 24 hours after the first daunorubicin dose to 25 patients and was continued until marrow recovery. Twenty-six patients received the same therapy without G-CSF. Patients receiving G-CSF had significantly fewer neutropenic days (29% of hospital days vs 84% for the group without G-CSF; P < 0.00005) and recovered neutrophil counts of more than 1000/mcL significantly sooner (16 days vs 26 days; P < 0.0005) than controls. Patients receiving G-CSF also had less febrile neutropenia (12% vs 42%; P < 0.05) and fewer documented infections than controls. There were no differences in transfusion requirements. Treatment outcome of the leukemia was similar in the two groups (96% CR rate on G-CSF; 80% for controls). G-CSF is a useful adjunct to induction chemotherapy in adult acute lymphoblastic leukemia.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.